Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

Beth Overmoyer, MD
Published: Friday, Dec 19, 2014


Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Overmoyer says in a study of about 30 patients with inflamatory breast cancer, it was determined that average time to tumor failure was 19 months, and 3-year overall survival was approximately 49%. Disease-free survival was also short.

The outlook for this patient population is particularly challenging, says Overmoyer. Currently, chemotherapy is the only option for these patients. Future research should focus on targeted therapies for inflammatory triple-negative breast cancer.

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Overmoyer says in a study of about 30 patients with inflamatory breast cancer, it was determined that average time to tumor failure was 19 months, and 3-year overall survival was approximately 49%. Disease-free survival was also short.

The outlook for this patient population is particularly challenging, says Overmoyer. Currently, chemotherapy is the only option for these patients. Future research should focus on targeted therapies for inflammatory triple-negative breast cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x